(Q53242492)

English

Preclinical safety testing of monoclonal antibodies: the significance of species relevance.

scientific article published in February 2007

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17268483

1 reference

Europe PubMed Central

Preclinical safety testing of monoclonal antibodies: the significance of species relevance. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17268483

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

Kathryn Chapman

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17268483

Nick Pullen

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17268483

Mark Graham

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17268483

Ian Ragan

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17268483

publication date

1 February 2007

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17268483

Nature Reviews Drug Discovery

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17268483

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17268483

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17268483

120-126

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17268483

Anti-infective monoclonal antibodies: perils and promise of development

1 reference

https://api.crossref.org/works/10.1038%2FNRD2242

31 March 2020

Monoclonal antibody successes in the clinic

1 reference

https://api.crossref.org/works/10.1038%2FNRD2242

31 March 2020

Monoclonal antibodies market

1 reference

https://api.crossref.org/works/10.1038%2FNRD2242

31 March 2020

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

1 reference

https://api.crossref.org/works/10.1038%2FNRD2242

31 March 2020

Loss of Siglec expression on T lymphocytes during human evolution

1 reference

https://api.crossref.org/works/10.1038%2FNRD2242

31 March 2020

Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FNRD2242

31 March 2020

Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4-specific monoclonal antibodies: CD4+ T-cell depletion is not required

1 reference

https://api.crossref.org/works/10.1038%2FNRD2242

31 March 2020

Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD2242

31 March 2020

The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma

1 reference

https://api.crossref.org/works/10.1038%2FNRD2242

31 March 2020

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2242

31 March 2020

The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab

1 reference

https://api.crossref.org/works/10.1038%2FNRD2242

31 March 2020

Scientific and regulatory considerations on the immunogenicity of biologics

1 reference

https://api.crossref.org/works/10.1038%2FNRD2242

31 March 2020

Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2242

31 March 2020

Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective

1 reference

https://api.crossref.org/works/10.1038%2FNRD2242

31 March 2020

Identifiers

10.1038/NRD2242

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17268483

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17268483

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53242492&oldid=2212043469"